Sleep Quality & Recovery — Peptide Research Overview
Sleep is the primary driver of growth hormone secretion, immune restoration, and neural detoxification. Several peptide compounds work through the growth hormone axis or direct sleep-regulatory pathways to enhance sleep quality, increase slow-wave sleep, and improve overnight recovery metrics.
Relevant Compounds
- Sermorelin — GHRH analog that stimulates natural pulsatile GH release, particularly during slow-wave sleep.
- DSIP — Delta Sleep-Inducing Peptide; a nonapeptide that modulates NREM sleep architecture and has anxiolytic properties.
- MK-677 — Oral ghrelin mimetic (ibutamoren) that significantly increases GH and IGF-1 levels. Studies show increased REM and slow-wave sleep.
- CJC-1295 / Ipamorelin — GHRH analog combined with selective GHRP. The combination amplifies pulsatile GH release at night without cortisol/prolactin elevation.
What the Research Shows
Sermorelin
[Human Trial] Sermorelin has been through Phase 3 trials (FDA-approved for pediatric GH deficiency; off-label in adults). Clinical use demonstrates increased IGF-1 and improved sleep quality scores in adults with GH deficiency. Bedtime dosing takes advantage of the natural GH pulse that occurs 1–2 hours after sleep onset.
DSIP
[Animal Study / Preliminary Human] DSIP was isolated from rabbit brain in 1977 and found to induce delta (slow-wave) sleep in multiple species. Small human studies show decreased sleep latency, increased slow-wave sleep percentage, and reduced cortisol reactivity. Evidence quality is limited by study size.
MK-677
[Human Trial] A randomized crossover trial (Copinschi et al., 1997) demonstrated that MK-677 increased slow-wave sleep by ~20% and REM sleep duration in healthy adults. Subsequent trials in elderly subjects confirmed improved sleep quality alongside increased IGF-1. Oral bioavailability makes compliance high.
CJC-1295 / Ipamorelin
[Animal Study / Preliminary Human] The combination of CJC-1295 (GHRH analog) with Ipamorelin (selective GHRP) produces additive GH release without significant elevation of cortisol or prolactin — a cleaner GH pulse than older GHRPs like GHRP-2 or GHRP-6. Improved sleep quality is commonly reported in clinical research use.
Evidence Summary
| Compound | Evidence Level | Primary Mechanism |
|---|---|---|
| Sermorelin | Human Trial | GHRH receptor activation, pulsatile GH release |
| DSIP | Animal / Preliminary Human | Delta sleep induction, cortisol modulation |
| MK-677 | Human Trial | Ghrelin receptor agonism, GH/IGF-1 elevation, SWS increase |
| CJC-1295 / Ipamorelin | Animal / Preliminary Human | Synergistic GHRH + GHRP GH pulse amplification |
Research Disclaimer
No compound listed on this page is FDA-approved for sleep quality improvement (Sermorelin is approved for pediatric GH deficiency only). This page is an educational summary of existing research. Consult your healthcare provider before using any peptide or experimental compound.
Track your compounds with Dosi
Log doses, monitor symptoms, and build a personal health timeline. Free to start.
Start Tracking Free →Educational use only. This content is for informational purposes only and does not constitute medical advice. Individual results vary. Always consult a licensed healthcare provider before starting any compound.